Related Experiment Video
Updated: May 5, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
[Cell therapy for stroke].
1Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine Sapporo Medical University.
Intravenous transplantation of autologous mesenchymal stem cells (MSCs) is a feasible and safe therapy for stroke patients. Further research is warranted to explore its potential for improving functional recovery after cerebral infarcts.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Cell Therapy
Context:
- Central Nervous System (CNS) diseases, including stroke, present significant challenges in functional recovery.
- Mesenchymal stem cells (MSCs) derived from bone marrow have shown promise in ameliorating deficits in various CNS conditions.
Purpose:
- To evaluate the feasibility and safety of utilizing autologous serum-expanded MSCs for intravenous cell therapy in stroke patients.
- To assess the potential of this cell therapy in improving functional outcomes post-stroke.
Summary:
- Twelve patients with stroke received intravenous infusions of thawed, cryopreserved autologous MSCs over 30 minutes.
- Serial evaluations confirmed no severe adverse cell-related effects during the study period.
- The intravenous administration of autologous MSCs in patients with cerebral infarcts demonstrated feasibility and safety.
Impact:
- This study suggests that autologous MSC therapy is a safe and feasible approach for stroke patients.
- The findings support further investigation into MSCs as a potential therapeutic strategy for enhancing functional recovery after stroke.
Related Concept Videos
Ischemic Stroke l: Introduction
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Stroke: Introduction and Types

